PAR-25-447-Full-Announcement.html

This document is a Notice of Funding Opportunity (NOFO) from the National Heart, Lung, and Blood Institute (NHLBI) for the TransOmics for Precision Medicine (TOPMed) program. The opportunity seeks applications to generate integrated genetic and multi-omics data to facilitate discovery of molecular mechanisms underlying Heart, Lung, Blood, and Sleep (HLBS) disorders. Critically, no direct funding will be provided; instead, applicants are expected to generate genomic and phenotypic data that will be deposited in public controlled-access databases like dbGaP and NHLBI's BioData Catalyst.

The NOFO is specifically targeting research that moves beyond genetic association cataloging to understanding how genetic factors contribute to HLBS diseases at molecular and cellular levels. The program aims to transform TOPMed from a genetic "Map to Mechanism" by potentially incorporating AI and machine learning tool sets to accelerate personalized medicine research. The opportunity utilizes the X01 activity code and is part of federal grant programs including Lung Diseases Research (CFDA 93.838), Cardiovascular Diseases Research (CFDA 93.837), and Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (CFDA 93.840). Investigators are encouraged to develop collaborative projects and meaningful research approaches in preparation for a future formal solicitation.